Biogen Expects Strong 2026 Profit as Alzheimer Drug Sales Accelerate
Biogen expects 2026 profit to beat estimates as sales of its Alzheimer drug Leqembi rise. Strong demand for new medicines helps offset declining MS drug sales.
Insights:
Biogen Inc. announced its 2026 adjusted-profit guidance today, February 6, 2026, providing a forecast that exceeded Wall Street estimates as the company continues its transition toward newer rare-disease and specialty medicines. The company, which operates extensively in the United States 
US, projected an adjusted profit range of $15.25 to $16.25 per share for 2026. This outlook is notably higher than the $14.92 per share average expectation previously held by analysts.
US, projected an adjusted profit range of $15.25 to $16.25 per share for 2026. This outlook is notably higher than the $14.92 per share average expectation previously held by analysts.
